Phase 2a Study of ABBV-142 for Treating Adults with Idiopathic Pulmonary Fibrosis Evaluating Safety, Tolerability, and Effectiveness with Placebo Comparison

What this Trial Is About

Idiopathic Pulmonary Fibrosis IPF is a rare, chronic lung disease that causes scarring of lung tissue, leading to shortness of breath, reduced lung function, and decreased quality of life. Researchers are evaluating different treatments for IPF using a platform study design, which allows multiple treatments to be tested under one protocol. This study specifically aims to assess the safety, tolerability, and effectiveness of the investigational drug ABBV-142 compared to placebo in adults with IPF. Participants will be randomly assigned to receive either ABBV-142 or a matching placebo for 52 weeks during a double-blind treatment phase, where neither participants nor doctors know who receives which treatment. After this, eligible participants may receive ABBV-142 for an additional 52 weeks in an open-label phase. The study includes regular visits to clinics or hospitals for treatment and monitoring. During the study, participants will undergo medical assessments, blood tests, and questionnaires to monitor the effects of the treatment and any side effects. Researchers will measure changes in lung function, specifically forced vital capacity FVC, and track adverse events over approximately 52 weeks. All participants will be followed for an additional 120 days after treatment to ensure safety and gather further data. The total participation duration may span over two years, depending on eligibility for the open-label phase.

Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis